ESMO 2023 | ACTIVATE: etigilimab and nivolumab in locally advanced/metastatic solid tumors

Meredith McKean, MD, MPH, Sarah Cannon Research Institute, London, UK, discusses findings from the Phase Ib/II ACTIVATE trial (NCT04761198) of etigilimab, an anti-TIGIT antibody, and nivolumab, an anti PD-1 checkpoint inhibitor, in patients with various solid tumors. Complete responses were recorded in cervical cancer and partial responses were observed in uveal melanoma. The safety profile of the investigational therapy was consistent with existing checkpoint inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.